Show simple item record

dc.contributor.authorWagstaff, John
dc.contributor.authorTodd, Ian D
dc.contributor.authorDeakin, David P
dc.contributor.authorWilkinson, Peter M
dc.contributor.authorScarffe, J Howard
dc.contributor.authorHarris, Martin
dc.contributor.authorJones, M
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-10-20T11:12:36Z
dc.date.available2010-10-20T11:12:36Z
dc.date.issued1987
dc.identifier.citationA randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma. 1987, 20 (1):53-8 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid3304688
dc.identifier.doi10.1007/BF00252960
dc.identifier.urihttp://hdl.handle.net/10541/113548
dc.description.abstractThis paper reports the 8-year results of comparing the use of two types of adjuvant chemotherapy following involved field radiotherapy for clinical stages I and II high-grade non-Hodgkin's lymphoma. Twenty-four patients received 6 weeks of VAP plus 2 years of oral maintenance chemotherapy, and 30 had six cycles of CMOPP. Four patients were not in complete remission at completion of i.v. chemotherapy (CR rate 91%). Ten patients (18.5%) have relapsed (VAP/M = 5; CMOPP = 5), with only two of these remaining alive, both of them being disease free. There have been three deaths from intercurrent causes, one from malignant melanoma and the other two from myocardial infarction. The relapse-free survivals at 2, 5 and 8 years were 80%, 76% & 76% respectively. The overall survivals at the same time points were 86%, 72% & 68%. There were no significant differences in either relapse-free or overall survival for either of the two treatment groups. The shorter period of weekly intravenous chemotherapy (VAP/M) was better tolerated than 36 weeks of CMOPP, and the former appears to produce equivalent results.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshClinical Trials as Topic
dc.subject.meshCyclophosphamide
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymphoma, Non-Hodgkin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrednisolone
dc.subject.meshProcarbazine
dc.subject.meshRandom Allocation
dc.subject.meshVincristine
dc.titleA randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractThis paper reports the 8-year results of comparing the use of two types of adjuvant chemotherapy following involved field radiotherapy for clinical stages I and II high-grade non-Hodgkin's lymphoma. Twenty-four patients received 6 weeks of VAP plus 2 years of oral maintenance chemotherapy, and 30 had six cycles of CMOPP. Four patients were not in complete remission at completion of i.v. chemotherapy (CR rate 91%). Ten patients (18.5%) have relapsed (VAP/M = 5; CMOPP = 5), with only two of these remaining alive, both of them being disease free. There have been three deaths from intercurrent causes, one from malignant melanoma and the other two from myocardial infarction. The relapse-free survivals at 2, 5 and 8 years were 80%, 76% & 76% respectively. The overall survivals at the same time points were 86%, 72% & 68%. There were no significant differences in either relapse-free or overall survival for either of the two treatment groups. The shorter period of weekly intravenous chemotherapy (VAP/M) was better tolerated than 36 weeks of CMOPP, and the former appears to produce equivalent results.


This item appears in the following Collection(s)

Show simple item record